Study design
Cancer
CANCER
A prospective single-arm phase 2 study and its protocol was registered at ClinicalTrials.gov (ClinicalTrials.gov identifier: NCT03443661,23/02/2018) and approved by the central ethics committee of the Cancer Hospital of Chinese Academy of Medical Science, Beijing, China, with ethical approval number: 15–134/1061.The study was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. All patients included in the study provided written informed consent.